1-3 of 3
Virginia Klimek, MD
Close
Sort by
Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD
Journal: Blood
Blood (2008) 112 (11): 3712.
https://doi.org/10.1182/blood.V112.11.3712.3712
Published: 2008
Journal Articles

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, Virginia Klimek, MD, Jorge Cortes, MD, Farhad Ravandi, MD, Willie M. Newsome, RN, Julie Dumouchel, Marja Dubay, Zoumei Li, Christiane Maroun, Eric Laille, Hagop Kantarjian, MD, Robert E. Martell, MD, Selina Luger, MD
Journal: Blood
Blood (2007) 110 (11): 444.
https://doi.org/10.1182/blood.V110.11.444.444
Published: 2007
Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD
Journal: Blood
Blood (2005) 106 (11): 1156.
https://doi.org/10.1182/blood.V106.11.1156.1156
Published: 2005